A Phase II Study Evaluating Orteronel, an Inhibitor of Androgen Biosynthesis, in Patients With Androgen Receptor (AR)-Expressing Metastatic Breast Cancer (MBC)

Authors: Yardley, Denise A., Young, Robyn R., Adelson, Kerin B., Silber, Andrea L., Najera, Jose E., Daniel, Davey B., Peacock, Nancy, Finney, Lindsey, Hoekstra, Susan J., Shastry, Mythili, Hainsworth, John D., Burris, Howard A.

Source: Clinical breast cancer. 22(3):269-278

Availability: http://explore.bl.uk/primo_library/libweb/action/display.do?tabs=detailsTab&gathStatTab=true&ct=display&fn=search&doc=ETOCvdc_100158218427.0x000001&indx=1&recIds=ETOCvdc_100158218427.0x000001

A Phase II Open Label Study of Everolimus in Combination With Endocrine Therapy in Resistant Hormone Receptor-Positive HER2-Negative Advanced Breast Cancer

Authors: Yardley, Denise A., Liggett, William, Mainwaring, Mark, Castrellon, Aurelio, Blakely, Laura, Hemphill, Brian, Anz, Bertrand, III, Young, Robyn R., Shastry, Mythili, DeBusk, Laura M., Hainsworth, John D., Burris, Howard A., III

Source: In Clinical Breast Cancer April 2020 20(2):89-97

Ramucirumab plus docetaxel versus placebo plus docetaxel in patients with locally advanced or metastatic urothelial carcinoma after platinum-based therapy (RANGE): overall survival and updated results of a randomised, double-blind, phase 3 trial

Authors: Wong, Suet-Lai Shirley, Tan, Thean Hsiang, Hovey, Elizabeth Jane, Clay, Timothy Dudley, Wan Ng, Siobhan Su, Rutten, Annemie, Machiels, Jean-Pascal, Dumez, Herlinde, Cheng, Susanna Yee-Shan, Ferrario, Cristiano, Sengeloev, Lisa, Jensen, Niels Viggo, Thibault, Constance, Laguerre, Brigitte, Joly, Florence, Culine, Stéphane, Becht, Catherine, Niegisch, Günter, Stöckle, Michael, Grimm, Marc-Oliver, Schwentner, Christina A, Schultze-Seemann, Wolfgang, Kalofonos, Haralambos, Mavroudis, Dimitrios, Papandreou, Christos, Karavasilis, Vasilis, Révész, Janos, Rosenbaum, Eli, Leibowitz-Amit, Raya, Kejzman, Daniel, Sarid, David, Scagliotti, Giorgio Vittorio, Bracarda, Sergio, Massari, Francesco, Osawa, Takahiro, Miyajima, Naoto, Shinohara, Nobuo, Fukuta, Fumimasa, Ohyama, Chikara, Obara, Wataru, Yamashita, Shinichi, Tomita, Yoshihiko, Kawai, Koji, Fukasawa, Satoshi, Oyama, Masafumi, Yonese, Junji, Nagata, Masayoshi, Uemura, Motohide, Nishimura, Kazuo, Kawakita, Mutsushi, Tsunemori, Hiroyuki, Hashine, Katsuyoshi, Inokuchi, Junichi, Yokomizo, Akira, Nagamori, Satoshi, Lee, Hyo Jin, Park, Se Hoon, Rha, Sun Young, Kim, Yu Jung, Lee, Yun-Gyoo, Vazquez Cortés, Leticia, Lorena Urzua Flores, Claudia, Blaisse, Reinoud J.B., Erdkamp, Fransiscus L.G., Aarts, Maureen J.B., Wojcik-Tomaszewska, Joanna, Tomczak, Piotr, Sikora-Kupis, Bozena, Schenker, Michael, Herzal, Alina Amalia, Udrea, Anghel Adrian, Karlov, Petr, Fomkin, Roman, Gajate Borau, Pablo, Grande, Enrique, Delgado Mignorance, Juan Ignacio, Su, Yu-Li, Li, Jian-Ri, Lin, Chien-Liang, Lin, Chia-Chi, Yeh, Su-Peng, Erman, Mustafa, Urun, Yuksel, Golovko, Yuriy, Bondarenko, Igor, Sinielnikov, Ivan, Crabb, Simon J., Syndikus, Isabel, Huddart, Robert, Sundar, Santhanam, Chowdhury, Simon, Sarwar, Naveed, Flaig, Thomas W., Pan, Chong Xian, Schwarz, James K., Cultrera, Jennifer Lyn, Acs, Peter Istvan, Hainsworth, John D., Herms, Benjamin T., Lawler, William Eyre, Lowe, Thomas Eugene, Petrylak, Daniel P ^*, de Wit, Ronald, Chi, Kim N, Drakaki, Alexandra, Sternberg, Cora N ^*, Nishiyama, Hiroyuki, Castellano, Daniel, Hussain, Syed A, Fléchon, Aude, Bamias, Aristotelis, Yu, Evan Y, van der Heijden, Michiel S, Matsubara, Nobuaki, Alekseev, Boris, Necchi, Andrea, Géczi, Lajos, Ou, Yen-Chuan, Coskun, Hasan Senol, Su, Wen-Pin, Bedke, Jens, Gakis, Georgios, Percent, Ivor J, Lee, Jae-Lyun, Tucci, Marcello, Semenov, Andrey, Laestadius, Fredrik, Peer, Avivit, Tortora, Giampaolo, Safina, Sufia, Garcia del Muro, Xavier, Rodriguez-Vida, Alejo, Cicin, Irfan, Harputluoglu, Hakan, Tagawa, Scott T, Vaishampayan, Ulka, Aragon-Ching, Jeanny B, Hamid, Oday, Liepa, Astra M, Wijayawardana, Sameera, Russo, Francesca, Walgren, Richard A, Zimmermann, Annamaria H, Hozak, Rebecca R, Bell-McGuinn, Katherine M, Powles, Thomas

Source: In The Lancet Oncology January 2020 21(1):105-120

Phase II trial of eribulin in patients who do not achieve pathologic complete response (pCR) following neoadjuvant chemotherapy

Authors: Yardley, Denise A., Peacock, Nancy, Daniel, Brooke, Anz, Betrand, Molthrop, David C., Shroff, Sonalee K., Young, Robyn, Jankov, Aleksander, Vander Woude, Amy, Shastry, Mythili, Pasek, Johanna, DeBusk, Laura M., Hainsworth, John D.

Source: Breast cancer research and treatment. 180(3):647-655

Availability: http://explore.bl.uk/primo_library/libweb/action/display.do?tabs=detailsTab&gathStatTab=true&ct=display&fn=search&doc=ETOCvdc_100171269666.0x000001&indx=1&recIds=ETOCvdc_100171269666.0x000001

A Randomized Phase II Study of Eribulin/Cyclophosphamide or Docetaxel/Cyclophosphamide as Neoadjuvant Therapy in Operable HER2-negative Breast Cancer

Authors: Yardley, Denise A., Shipley, Dianna, Zubkus, John, Wright, Gail L., Ward, Patrick J., Mani, Aruna, Shastry, Mythili, Finney, Lindsey, DeBusk, Laura, Hainsworth, John D.

Source: In Clinical Breast Cancer February 2019 19(1):1-9

Cabazitaxel Plus Lapatinib as Therapy for HER2+ Metastatic Breast Cancer With Intracranial Metastases: Results of a Dose-finding Study

Authors: Yardley, Denise A., Hart, Lowell L., Ward, Patrick J., Wright, Gail L., Shastry, Mythili, Finney, Lindsey, DeBusk, Laura M., Hainsworth, John D.

Source: In Clinical Breast Cancer October 2018 18(5):e781-e787

Renal Cell Carcinoma Presenting as Carcinoma of Unknown Primary Site: Recognition of a Treatable Patient Subset

Authors: Greco, F. Anthony, Hainsworth, John D.

Source: In Clinical Genitourinary Cancer August 2018 16(4):e893-e898

Phase II trial of preoperative pemetrexed plus carboplatin in patients with stage IB-III nonsquamous non-small cell lung cancer (NSCLC)

Authors: Hainsworth, John D., Waterhouse, David M., Shih, Kent C., Boccia, Ralph V., Priego, Victor M., McCleod, Michael J., Kudrik, Fred J., Mitchell, Reed Brian, Burris, Howard A., III, Greco, F. Anthony, Spigel, David R.

Source: In Lung Cancer April 2018 118:6-12

Amrubicin and carboplatin with pegfilgrastim in patients with extensive stage small cell lung cancer: A phase II trial of the Sarah Cannon Oncology Research Consortium

Authors: Spigel, David R., Hainsworth, John D., Shipley, Dianna L., Mekhail, Tarek M., Zubkus, John D., Waterhouse, David M., Daniel, Davey B., Burris, Howard A., III, Greco, F. Anthony

Source: In Lung Cancer March 2018 117:38-43

Phase I/II study of bevacizumab with BKM120, an oral PI3K inhibitor, in patients with refractory solid tumors (phase I) and relapsed/refractory glioblastoma (phase II)

Authors: Hainsworth, John D., Becker, Kevin P., Mekhail, Tarek, Chowdhary, Sajeel A., Eakle, Janice Faulkner, Wright, David, Langdon, Robert M., Yost, Kathleen J., Padula, Gilbert Darin Anthony, West-Osterfield, Kimberly, Scarberry, Meredith, Shaifer, Candice A., Shastry, Mythili, Burris, Howard A., Shih, Kent

Source: Journal of neuro-oncology. 144(2):303-311

Availability: http://explore.bl.uk/primo_library/libweb/action/display.do?tabs=detailsTab&gathStatTab=true&ct=display&fn=search&doc=ETOCvdc_100118716829.0x000001&indx=1&recIds=ETOCvdc_100118716829.0x000001

A Randomized, Double‐Blinded, Phase II Trial of Carboplatin and Pemetrexed with or without Apatorsen (OGX‐427) in Patients with Previously Untreated Stage IV Non‐Squamous‐Non‐Small‐Cell Lung Cancer: The SPRUCE Trial

Authors: Spigel, David R., Shipley, Dianna L., Waterhouse, David M., Jones, Suzanne F., Ward, Patrick J., Shih, Kent C., Hemphill, Brian, McCleod, Michael, Whorf, Robert C., Page, Ray D., Stilwill, Joseph, Mekhail, Tarek, Jacobs, Cindy, Burris, Howard A., Hainsworth, John D.

Source: Oncologist. 24(12):e1409-e1416

Availability: http://explore.bl.uk/primo_library/libweb/action/display.do?tabs=detailsTab&gathStatTab=true&ct=display&fn=search&doc=ETOCvdc_100093957898.0x000001&indx=1&recIds=ETOCvdc_100093957898.0x000001

Sorafenib and continued erlotinib or sorafenib alone in patients with advanced non-small cell lung cancer progressing on erlotinib: A randomized phase II study of the Sarah Cannon Research Institute (SCRI)

Authors: Spigel, David R., Rubin, Mark S., Gian, Victor G., Shipley, Dianna L., Burris, Howard A., III, Kosloff, Rebecca A., Shih, Kent C., Quinn, Raven, Greco, F. Anthony, Hainsworth, John D.

Source: In Lung Cancer November 2017 113:79-84

Panitumumab, Gemcitabine, and Carboplatin as Treatment for Women With Metastatic Triple-Negative Breast Cancer: A Sarah Cannon Research Institute Phase II Trial

Authors: Yardley, Denise A., Ward, Patrick J., Daniel, Brooke R., Eakle, Janice F., Lamar, Ruth E., Lane, Cassie M., Hainsworth, John D.

Source: In Clinical Breast Cancer October 2016 16(5):349-355

Sorafenib Plus Ixabepilone as First-Line Treatment of Metastatic HER2-Negative Breast Cancer: A Sarah Cannon Research Institute Phase I/II Trial

Authors: Yardley, Denise A., Dickson, Natalie, Drosick, David, Earwood, Chris, Inhorn, Roger, Murphy, Patrick, Hainsworth, John D.

Source: In Clinical Breast Cancer June 2016 16(3):180-187

Everolimus versus sunitinib for patients with metastatic non-clear cell renal cell carcinoma (ASPEN): a multicentre, open-label, randomised phase 2 trial

Authors: Armstrong, Andrew J ^*, Halabi, Susan, Eisen, Tim, Broderick, Samuel, Stadler, Walter M, Jones, Robert J, Garcia, Jorge A, Vaishampayan, Ulka N, Picus, Joel, Hawkins, Robert E, Hainsworth, John D, Kollmannsberger, Christian K, Logan, Theodore F, Puzanov, Igor, Pickering, Lisa M, Ryan, Christopher W, Protheroe, Andrew, Lusk, Christine M, Oberg, Sadie, George, Daniel J

Source: In The Lancet Oncology March 2016 17(3):378-388

MyPathway Human Epidermal Growth Factor Receptor 2 Basket Study: Pertuzumab + Trastuzumab Treatment of a Tissue-Agnostic Cohort of Patients With Human Epidermal Growth Factor Receptor 2–Altered Advanced Solid Tumors.

Authors: Sweeney, Christopher J., Hainsworth, John D., Bose, Ron, Burris, Howard A., Kurzrock, Razelle, Swanton, Charles, Friedman, Claire F., Spigel, David R., Szado, Tania, Schulze, Katja, Price, Richard, Malato, Julia, Lo, Amy A., Levy, Jonathan, Wang, Yong, Yu, Wei, Meric-Bernstam, Funda

Source: Journal of Clinical Oncology; 1/20/2024, Vol. 42 Issue 3, p258-265, 10p

Neoadjuvant Ixabepilone/Carboplatin/Trastuzumab in HER2-Positive Operable Breast Cancer: A Phase II Trial of the Sarah Cannon Research Institute

Authors: Yardley, Denise A., Zubkus, John D., Eakle, Janice F., Bechhold, Rebecca G., Finney, Lindsey, Daniel, Davey, Daniel, Brooke, Hainsworth, John D.

Source: In Clinical Breast Cancer August 2015 15(4):251-258

Pivotal ERIVANCE basal cell carcinoma (BCC) study: 12-month update of efficacy and safety of vismodegib in advanced BCC

Authors: Sekulic, Aleksandar, Migden, Michael R., Lewis, Karl, Hainsworth, John D., Solomon, James A., Yoo, Simon, Arron, Sarah T., Friedlander, Philip A., Marmur, Ellen, Rudin, Charles M., Chang, Anne Lynn S., Dirix, Luc, Hou, Jeannie, Yue, Huibin, Hauschild, Axel

Source: In Journal of the American Academy of Dermatology June 2015 72(6):1021-1026

First-Line Carboplatin, Pemetrexed, and Panitumumab in Patients with Advanced Non-Squamous KRAS Wild Type (WT) Non-Small-Cell Lung Cancer (NSCLC)

Authors: Spigel, David R., Mekhail, Tarek M., Waterhouse, David, Hadley, Terence, Webb, Charles, Burris, Howard A., Hainsworth, John D., Greco, F. Anthony

Source: Cancer investigation. 35(8):541-546

Availability: http://explore.bl.uk/primo_library/libweb/action/display.do?tabs=detailsTab&gathStatTab=true&ct=display&fn=search&doc=ETOCvdc_100104101382.0x000001&indx=1&recIds=ETOCvdc_100104101382.0x000001

Circulating Tumor Cells in a Phase 3 Study of Docetaxel and Prednisone with or without Lenalidomide in Metastatic Castration-resistant Prostate Cancer

Authors: Vogelzang, Nicholas J., Fizazi, Karim, Burke, John M., De Wit, Ronald, Bellmunt, Joaquim, Hutson, Thomas E., Crane, Edward, Berry, William R., Doner, Kevin, Hainsworth, John D., Wiechno, Pawel J., Liu, Kejian, Waldman, Michelle F., Gandhi, Anita, Barton, Debora, Jungnelius, Ulf, Fandi, Abderrahim, Sternberg, Cora N., Petrylak, Daniel P.

Source: European urology. 71(2):168-171

Availability: http://explore.bl.uk/primo_library/libweb/action/display.do?tabs=detailsTab&gathStatTab=true&ct=display&fn=search&doc=ETOCvdc_100042916429.0x000001&indx=1&recIds=ETOCvdc_100042916429.0x000001